# Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

> **NCT02240537** · PHASE1 · UNKNOWN · sponsor: **Benovus Bio, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Acute Myelogenous Leukemia (AML)
- Multiple Myeloma (MM)
- Myelodysplastic Syndrome (MDS)
- Smoldering Multiple Myeloma (sMM)

## Interventions

- **DRUG:** Sargramostim
- **DRUG:** BB-MPI-03
- **DRUG:** Montanide

## Key facts

- **NCT ID:** NCT02240537
- **Lead sponsor:** Benovus Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-01
- **Primary completion:** 2016-12
- **Final completion:** 2017-06
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2016-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240537, "Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02240537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*